mulative incidence approximately 0.055%/year) (p < 0.001). Due to high incidence of thrombotic recurrences and hemorrhagic complications while using oral anticoagulants, acetylsalicylic acid was initiated; no thrombotic episodes were recorded while using this drug. Protein C and protein S deficiency were found in nine and two patients, respectively. Two patients had lupus anticoagulant and two activated protein C resistance (APCR) without FV Leiden mutation (APCR test was negative after initial screening). Fifteen patients had no thrombophilic abnormalities. These data suggest that protease inhibitors could be a risk factor for venous thrombosis not due to thrombophilic abnormalities but likely related to abnormalities in platelets or endothelium. Key Words: Venous thrombosis-AIDS-Protease inhibitors-Thrombophilia. ing complications, thrombosis was commonly considered as infrequent in these patients. Although the number of publications on this issue increased in the past few years, reports of thrombosis complicating AIDS are still relatively scarce (7) (8) (9) (10) (11) (12) (13) . Therefore, if thrombosis becomes repetitive in a population never affected by this complication (nearly an epidemic pattern), it becomes a diagnostic and therapeutic problem. Because an unusual number of thrombotic events associated with AIDS appeared at our service during the past years, we considered it necessary to determine the etiology of these adverse events. The objective of this report was to report the clinical characteristics and hemostatic laboratory findings of 28 patients with AIDS who experienced venous thrombotic events, an uncommon manifestation associated with this viral disease.
PATIENTS AND METHODS
Our department solely cares for patients with AIDS. Since the department initiated activities, approximately 2,700 patients have been seen over a 12-year period. Patients infected with human immunodeficiency virus in different stages of infection are referred to other health care centers. Six hundred patients were seen during 6 years before availability of protease inhibitors. After initiating use of protease inhibitors (end of 1997, 5 years), 2,100 patients have been seen. As a result of this data, between 1,500 and 2,000 outpatient appointments are scheduled each month; therefore, our service is the largest AIDS clinical department in Mexico and one of the largest in Latin America. The majority of patients are homosexual men (91% of the population). Conventional treatment includes HAART regimen (88% of patients) based on use of protease inhibitors.
From January 1999 to June 2002, 28 adult male homosexual patients with AIDS experienced 34 thrombotic events. During this same period, 1,550 patients were seen in total. According to the 1993 Centers for Disease Control (CDC) classification, all patients with thrombosis fulfilled criteria to be considered as having AIDS. At the moment when the thrombotic event was diagnosed, all but three patients were receiving HAART regimen at worldwide-accepted doses. Two patients received successful double nucleoside analog therapy and the remaining patient was not receiving treatment. All patients received a prophylactic regimen with trimethoprim/sulfamethoxazole, orally every day (160/800 mg).
In every patient, clinical diagnosis of deep venous thrombosis was confirmed by venography. Pulmonary thrombosis was documented by ventilation-perfusion scanning, and renal venous thrombosis was documented by renal nuclear scanning using worldwide accepted criteria.
Because we had no clue to the possible etiology of venous thrombosis, complete thrombogenic screening was performed as recently suggested (14) . Prothrombin time (PT) and activated partial thromboplastin time (APTT) tests as well as platelet counts were performed at diagnosis and then weekly. PT and APTT tests and plasma concentrations of FVII and fibrinogen (Diagnostica Stago, France) were done at the moment of performing the thrombophilia test to exclude the possibility of liver disease or any effect of oral anticoagulants. All thrombophilia tests were per-formed at least 3 months after the thrombotic event once oral anticoagulants were discontinued or while the patient was receiving acetylsalicylic acid. Plasma samples for antithrombin-III (AT-III) levels were obtained once oral anticoagulants or acetylsalicylic acid were begun.
We performed a chromogenic assay to evaluate functional levels of AT-III (Stachrom AT-III, Diagnostica Stago) and clotting assays to evaluate protein C (PC), and protein S (PS) (Staclot Protein C and Staclot Protein S, Diagnostica Stago). Also, commercially available kits for lupus anticoagulant (normal ratio < 1.4, DVVtest, DW confirm, American Diagnostica, USA), modified activated protein C resistance (APCR) (normal ratio >2.0, Coatest + APC Resistance V-S, Chromogenix, Sweden), and anticardiolipin antibodies (normal value <10 U, Sanofi Diagnostics Pasteur, France) were used to evaluate presence of these abnormalities. In patients with positive APCR test results, FV Leiden analysis was performed as described elsewhere (15) . G20210A mutation in the prothrombin gene was evaluated according to the previously described method (16) .
Descriptive statistics were performed for demographic data. Data are shown as medians and ranges as needed. Chi square test was used to establish any difference between frequencies of thrombosis during periods of treatment with and without protease inhibitors. All statistical analyses were performed using EPISTAT program (Epistat Services, Tracey, Gustafson, Sweden). A p value < 0.05 was considered significant.
This research was carried out according to principles of the Declaration of Helsinki. The Ethics Committee of our Hospital approved the study. All patients were informed about the nature of the study and signed consent was obtained previous to blood being drawn.
RESULTS
Median age for this group of patients with AIDS and venous thrombosis was 38.3 years (range, 24 to 56 years). Median time from HIV infection to thrombosis was 40.5 months (range, 3 to 108 months). Except for three patients, all received HAART regimen. For patients receiving protease inhibitors, median time from initiation of these drugs to thrombosis was 7 months (range, 1 to 24 months). Mean TCD4+ cell count for the entire group was 66 cells/m3 (range, 3 to 668 TCD4+ cells/m3). Twelve patients had 100 to 200 TCD4+ cells/mm3 (43%) and 16 patients had fewer than 100 TCD4+ cells/mm3 (57%).
Analysis of the therapy is shown in seen at our service during the 42-month study period, was 1.52% (cumulative incidence = 0.30%/year). On the other hand, only two venous thrombotic events were diagnosed among 600 patients cared for in the era of double nucleoside analog therapy (0.33%, cumulative incidence approximately 0.055%/year). The difference between the two periods was statistically significant (p < 0.001). Only one patient died (patient number 7) due to a non-Hodgkin lymphoma diagnosed 38 months after the thrombotic episode. For the entire group, median survival since last venous thrombosis was 35 months (range, 8 to 76 months). Malignant disease did not develop in any patient still alive. Immediately after diagnosis of thrombosis, IV standard heparin (24,000 U/day) was indicated. After the acute phase, the first four patients received oral anticoagulants (target INR 2-3). Due to the difficulty in maintaining a stable INR <3, multiple hemorrhagic episodes were recorded during follow-up of these four patients (skin and gastrointestinal bleeding, two severe episodes requiring blood transfusion). Moreover, a second thrombotic episode was recorded in patients despite their receiving oral anticoagulants at therapeutic ranges (last recorded INR values immediately before thrombosis were between 2.14 and 3.05). Due to these hemorrhagic experiences and because of lack of information concerning appropriate treatment for thrombosis in patients with AIDS, we decided that oral anticoagulants or any other antithrombotic drug should not be indicated if more patients were affected by thrombosis. Unfortunately, three additional recurrent thrombotic events occurred. After the sixth relapsing thrombotic episode, acetylsalicylic acid 350 to 500 mg orally every day was indicated for all subsequent patients. No thrombotic relapses or bleeding episodes were recorded in these patients while they were receiving this antiplatelet drug. Table 2 shows results of thrombophilic screening. All samples were obtained when oral anticoagulants were stopped or while the patient was receiving acetylsalicylic acid. At moment of performing the thrombophilic tests, PT and APTT tests were between normal ranges, as were fibrinogen and FVII plasma levels. Nine patients had PS deficiency, two had PC deficiency, and none had AT-III deficiency. Lupus anticoagulant was positive in two cases. Another two patients had APCR and in both FV Leiden mutation was not found. Four and 8 months later, APCR tests were negative for both patients. No patient had G20210A prothrombin gene mutation. Two patients had two simultaneous abnormalities in thrombophilic screening. All patients not receiving protease inhibitors had normal thrombophilic screening.
DISCUSSION
Thrombosis is still an unusual complication in patients with AIDS (7, (17) (18) (19) . Until very recently, our experience was not different because after 6 years of working in the AIDS area, only two venous thrombotic events were diagnosed among 600 patients seen during the era of double nucleoside analog therapy. One of these two patients had familial PC deficiency; therefore, this patient had a high possibility for suffering a thrombotic complication, independent of the HIV infection. From this point of view, we assume that since the opening of our service, one true AIDS-related thrombotic event was recorded.
In a relatively short time, we found a dramatic increase in venous thrombosis. The majority of patients had one thrombotic episode and some experienced life-threatening thrombosis: one renal vein thrombosis and two pulmonary thromboembolic events. Six patients had second thrombosis despite the fact that three had INR above therapeutic ranges, a fact suggesting severe and permanent thrombophilic condition. Despite this increase of venous thrombosis, no arterial thrombose have been recorded.
Of course, when the first cases were diagnosed we did not have a clear idea either concerning the possible etiology of thrombosis or the best therapeutic alternative to apply. Several conditions have been associated with thrombosis in patients with AIDS. The most frequent association was established with abnormally low PS levels (12, (20) (21) (22) (23) (24) ; however, several other associations were also found: cytomegalovirus infection (25) (26) (27) ; acquired PC deficiency (10,28); use of megestrol acetate (29, 30) ; parenteral nutrition (31); acquired heparin cofactor II deficiency (32); hypofibrinolytic state (33); or lupus anticoagulant (34) (35) (36) . In agreement with previous reports, PS and PC deficiency and lupus anticoagulants were found in 32%, 7%, and 7% of our patients, respectively. At time of thrombosis, no patient included in this report had cytomegalovirus infection nor was any patient receiving parenteral nutrition. Although nine patients received megestrol acetate at time of thrombosis, this appears not to be a factor asso- ciated with thrombotic events in that this drug was largely used prior to the era of the protease inhibitors (183 of 600 patients). Certain specific facts of this report deserve special attention. For example, although frequency of PS deficiency among our patients was similar to previous reports, frequency of lupus anticoagulant was higher than expected at our service according to previous hemostatic screening performed at the service (currently 7% vs. a previous 0.5%, unpublished data). Furthermore, both patients in this report with lupus anticoagulant had severe, extensive, and repetitive (patient number 1) thrombotic episodes. On the other hand, we found two patients with acquired APCR (FV Leiden negative). We considered these cases as having acquired disorder because 1) FV Leiden mutation was not found, and 2) a second APCR test results was negative twice after initial positive test. To our knowledge, these are the first cases of acquired APCR associated with AIDS.
Although we performed thrombophilic screening for abnormalities principally associated with venous thrombosis, a specific abnormality could not be found in 15 patients. Of course, there still remain two major components of the coagulation system that may explain thrombosis: platelets and endothelium. With regard to platelets, it is noteworthy that no relapsing thrombotic episodes were recorded in the six patients with recurrent thrombosis after antithrombotic monotherapy with acetylsalicylic acid was started. In addition, in patients experiencing only one thrombotic episode, no thrombotic episodes were recorded while patients were administered this antiplatelet drug. This is solely an observation because we do not have sufficient data to support a possible etiologic role of platelets in thrombosis of these patients. With regard to endothelium, it was previously recognized that HIV infection was associated with endothelial dysfunction (37) (38) (39) .
Our data strongly suggested that protease inhibitors could be a risk factor for inducing venous thrombosis. Some information published in previous reports appears to reinforce our observation. First, in agreement with our data, at least three reports associated a protease inhibitor with venous thrombotic events (40) (41) (42) ; second, according to another report (43) protease inhibitors were able to induce endothelial dysfunction and a possible thrombophilic condition. Of course, three patients in this report were not receiving protease inhibitors at moment of venous thrombosis and in no positive thrombophilic test result was found. In addition to this latter consideration, our results continue to suggest that these antiviral agents may have a role in inducing venous thrombosis, a condition not associated with pure thrombophilic abnormalities but likely related to abnormalities in platelets or endothelium. In addition to the cause of precipitating venous thrombosis, it may be possible to hypothesize that AIDS itself may be a multifactorial thrombophilic condition (a cellular dysfunctional scenario affecting platelets and/or endothelium) that would be unmasked by protease inhibitor therapy. From this point of view, protease inhibitors could be considered as permissive drugs for venous thrombosis in AIDS patients.
In summary, we described herein our experience with a sudden outbreak of thrombotic events in patients with AIDS. Our results suggest a possible association between use of antiretroviral therapy with protease inhibitors and venous thrombosis in these patients. It is interesting that such a great number of patients experienced this complication in a relatively short period of time compared to previous reports. It is possible that protease inhibitors are able to down-regulate the natural anticoagulant system in some patients or that protease inhibitors may have an effect in-ducing endothelial or platelet dysfunction conditioning or increasing a thrombophilic condition. Acetylsalicylic acid appears to be effective in preventing relapsing episodes of thrombosis. Further prospective studies concerning nature of the thrombophilic condition affecting these patients are warranted.
